Global Monoclonal Antibodies (mAbs) Biosimilars Supply, Demand and Key Producers, 2026-2032
The global Monoclonal Antibodies (mAbs) Biosimilars market size is expected to reach $ 47538 million by 2032, rising at a market growth of 16.8% CAGR during the forecast period (2026-2032).
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy’s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple “first biosimilar to a blockbuster mAb” competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
This report studies the global Monoclonal Antibodies (mAbs) Biosimilars demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Monoclonal Antibodies (mAbs) Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Monoclonal Antibodies (mAbs) Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Monoclonal Antibodies (mAbs) Biosimilars total market, 2021-2032, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Monoclonal Antibodies (mAbs) Biosimilars total market, key domestic companies, and share, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars revenue by player, revenue and market share 2021-2026, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by Type, CAGR, 2021-2032, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Monoclonal Antibodies (mAbs) Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion,Inc., SamsungBioepisCo.,Ltd., AmgenInc., SandozGroupAG, PfizerInc., BioconBiologicsLimited, FreseniusKabiAG, FormyconAG, Alvotech, TevaPharmaceuticalIndustriesLtd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Monoclonal Antibodies (mAbs) Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Monoclonal Antibodies (mAbs) Biosimilars Market, By Region:
1. How big is the global Monoclonal Antibodies (mAbs) Biosimilars market?
2. What is the demand of the global Monoclonal Antibodies (mAbs) Biosimilars market?
3. What is the year over year growth of the global Monoclonal Antibodies (mAbs) Biosimilars market?
4. What is the total value of the global Monoclonal Antibodies (mAbs) Biosimilars market?
5. Who are the Major Players in the global Monoclonal Antibodies (mAbs) Biosimilars market?
6. What are the growth factors driving the market demand?
Monoclonal antibody (mAb) biosimilars are highly similar, lower-cost versions of approved, brand-name biological drugs used to treat cancers, autoimmune diseases, and infections. They are developed after a reference mAb's patent expires and are proven to have no clinically meaningful differences in efficacy, safety, or quality compared to the original, providing greater patient access to advanced therapies.
The global supply structure has become increasingly multi-polar. SouthKorean companies such as Celltrion and SamsungBioepis have built broad, globally visible portfolios across immunology, oncology, ophthalmology and hematology. Large western pharmaceutical and generic groups such as Amgen, Pfizer, Sandoz, FreseniusKabi, Organon and BoehringerIngelheim compete through regulatory scale, commercialization networks and established healthcare-system access. Indian companies such as BioconBiologics, Dr.Reddy’s, Intas/Accord and Lupin combine cost-competitive development with growing regulated-market ambitions. Chinese companies such as Henlius, Bio-Thera, Qilu and Innovent are moving from domestic approvals toward international filings and licensing partnerships. The market is also shaped by partnership models, such as Alvotech/Teva, Formycon/FreseniusKabi, Bio-Thera/STADA and Bio-Thera/GedeonRichter, where one party often leads development and manufacturing while another leads regional commercialization.
Demand growth is being driven by the expansion of biosimilar competition into high-spend reference biologics. The first major wave centered on oncology and immunology products such as trastuzumab, bevacizumab, rituximab, infliximab and adalimumab. The next wave is expanding into ustekinumab, tocilizumab, ranibizumab, aflibercept, denosumab, eculizumab, omalizumab and other antibody-related products. However, regulatory approval alone does not guarantee rapid uptake. The ASPE report on U.S. biosimilar market entry highlights that market size and entry order affect biosimilar revenues, and that markets such as bevacizumab, rituximab and trastuzumab took time to reach peak biosimilar share. In practice, adoption depends on payer policy, tendering rules, formulary access, physician confidence, patient switching, interchangeability status, originator contracting and supply reliability.
From a product and strategy perspective, the market is moving beyond simple “first biosimilar to a blockbuster mAb” competition. Future differentiation will increasingly depend on high-concentration formulations, citrate-free presentations, prefilled syringes, autoinjectors, interchangeability designations, global dossier reuse, real-world evidence, manufacturing cost control and broad market-access execution. The U.S. and Europe will remain the most valuable regulated markets, but China, India, Latin America, the Middle East and Southeast Asia are increasingly important for volume growth and regional commercialization partnerships. The long-term outlook is positive because many high-value biologics are entering or approaching biosimilar competition, but price erosion can be severe once multiple entrants compete. Companies with integrated R&D, manufacturing, regulatory and commercialization capabilities are therefore better positioned than firms that rely only on low-cost production or single-market approvals.
This report studies the global Monoclonal Antibodies (mAbs) Biosimilars demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Monoclonal Antibodies (mAbs) Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Monoclonal Antibodies (mAbs) Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Monoclonal Antibodies (mAbs) Biosimilars total market, 2021-2032, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Monoclonal Antibodies (mAbs) Biosimilars total market, key domestic companies, and share, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars revenue by player, revenue and market share 2021-2026, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by Type, CAGR, 2021-2032, (USD Million)
Global Monoclonal Antibodies (mAbs) Biosimilars total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Monoclonal Antibodies (mAbs) Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Celltrion,Inc., SamsungBioepisCo.,Ltd., AmgenInc., SandozGroupAG, PfizerInc., BioconBiologicsLimited, FreseniusKabiAG, FormyconAG, Alvotech, TevaPharmaceuticalIndustriesLtd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Monoclonal Antibodies (mAbs) Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Monoclonal Antibodies (mAbs) Biosimilars Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Adalimumab Biosimilars
- Infliximab Biosimilars
- Rituximab Biosimilars
- Trastuzumab Biosimilars
- Bevacizumab Biosimilars
- Ranibizumab Biosimilars
- Ustekinumab Biosimilars
- Tocilizumab Biosimilars
- Denosumab Biosimilars
- Other mAb Biosimilars
- Intravenous Infusion Vials
- Subcutaneous Prefilled Syringes
- Autoinjectors
- Lyophilized Powder for Injection
- Concentrate for Solution for Infusion
- Ophthalmic Intravitreal Injection
- Multiple Presentations
- TNF-? Inhibitors
- CD20-targeting Antibodies
- HER2-targeting Antibodies
- VEGF/VEGF-A Inhibitors
- IL-6R Inhibitors
- IL-12/23 Inhibitors
- RANKL Inhibitors
- C5 Complement Inhibitors
- IgE Inhibitors
- Other Targets
- Oncology
- Autoimmune and Inflammatory Diseases
- Ophthalmology
- Bone Disease and Osteoporosis
- Hematology and Rare Diseases
- Asthma and Allergy
- Other
- Celltrion,Inc.
- SamsungBioepisCo.,Ltd.
- AmgenInc.
- SandozGroupAG
- PfizerInc.
- BioconBiologicsLimited
- FreseniusKabiAG
- FormyconAG
- Alvotech
- TevaPharmaceuticalIndustriesLtd.
- Organon&Co.
- BoehringerIngelheimInternationalGmbH
- CoherusBioSciences,Inc.
- mAbxience
- STADAArzneimittelAG
- GedeonRichterPlc.
- Bio-TheraSolutions,Ltd.
- ShanghaiHenliusBiotech,Inc.
- QiluPharmaceuticalCo.,Ltd.
- InnoventBiologics,Inc.
- Dr.Reddy’sLaboratoriesLtd.
- IntasPharmaceuticalsLtd.
- AccordHealthcare
- LupinLimited
- ZydusLifesciencesLimited
- RelianceLifeSciencesPvt.Ltd.
- PrestigeBiopharmaLimited
- AmnealPharmaceuticals,Inc.
- PolpharmaBiologicsB.V.
- Mabwell(Shanghai)BioscienceCo.,Ltd.
- ZhejiangHisunPharmaceuticalCo.,Ltd.
- JiangsuHengruiPharmaceuticalsCo.,Ltd.
- LivzonPharmaceuticalGroupInc.
- SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
- MabpharmLimited
- BioXpressTherapeuticsSA
- TanvexBioPharma,Inc.
- CelltrionHealthcare
- AmegaBiotech
- ProbiomedS.A.deC.V.
1. How big is the global Monoclonal Antibodies (mAbs) Biosimilars market?
2. What is the demand of the global Monoclonal Antibodies (mAbs) Biosimilars market?
3. What is the year over year growth of the global Monoclonal Antibodies (mAbs) Biosimilars market?
4. What is the total value of the global Monoclonal Antibodies (mAbs) Biosimilars market?
5. Who are the Major Players in the global Monoclonal Antibodies (mAbs) Biosimilars market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Monoclonal Antibodies (mAbs) Biosimilars Introduction
1.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Monoclonal Antibodies (mAbs) Biosimilars Total Market by Region (by Headquarter Location)
1.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.3 China Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.4 Europe Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.5 Japan Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.6 South Korea Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.7 ASEAN Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.8 India Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.2 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region
2.2.1 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026)
2.2.2 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Region (2027-2032)
2.3 United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.4 China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.5 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.6 Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.7 South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.8 ASEAN Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.9 India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
3 WORLD MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS COMPANIES COMPETITIVE ANALYSIS
3.1 World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Monoclonal Antibodies (mAbs) Biosimilars Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Monoclonal Antibodies (mAbs) Biosimilars in 2025
3.2.3 Global Concentration Ratios (CR8) for Monoclonal Antibodies (mAbs) Biosimilars in 2025
3.3 Monoclonal Antibodies (mAbs) Biosimilars Company Evaluation Quadrant
3.4 Monoclonal Antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.4.1 Monoclonal Antibodies (mAbs) Biosimilars Market: Region Footprint
3.4.2 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.4.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison
4.2.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies and Market Share, 2021-2026
4.3.1 United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026)
4.4 China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue and Market Share, 2021-2026
4.4.1 China Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026)
4.5 Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Adalimumab Biosimilars
5.2.2 Infliximab Biosimilars
5.2.3 Rituximab Biosimilars
5.2.4 Trastuzumab Biosimilars
5.2.5 Bevacizumab Biosimilars
5.2.6 Ranibizumab Biosimilars
5.2.7 Ustekinumab Biosimilars
5.2.8 Tocilizumab Biosimilars
5.2.9 Denosumab Biosimilars
5.3 Market Segment by Type
5.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
5.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2027-2032)
5.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Intravenous Infusion Vials
6.2.2 Subcutaneous Prefilled Syringes
6.2.3 Autoinjectors
6.2.4 Lyophilized Powder for Injection
6.2.5 Concentrate for Solution for Infusion
6.2.6 Ophthalmic Intravitreal Injection
6.2.7 Multiple Presentations
6.3 Market Segment by Dosage Form
6.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2021-2026)
6.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2027-2032)
6.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2027-2032)
7 MARKET ANALYSIS BY MOLECULAR TARGET
7.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Molecular Target: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Molecular Target
7.2.1 TNF-? Inhibitors
7.2.2 CD20-targeting Antibodies
7.2.3 HER2-targeting Antibodies
7.2.4 VEGF/VEGF-A Inhibitors
7.2.5 IL-6R Inhibitors
7.2.6 IL-12/23 Inhibitors
7.2.7 RANKL Inhibitors
7.2.8 C5 Complement Inhibitors
7.2.9 IgE Inhibitors
7.3 Market Segment by Molecular Target
7.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2021-2026)
7.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2027-2032)
7.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Oncology
8.2.2 Autoimmune and Inflammatory Diseases
8.2.3 Ophthalmology
8.2.4 Bone Disease and Osteoporosis
8.2.5 Hematology and Rare Diseases
8.2.6 Asthma and Allergy
8.2.7 Other
8.3 Market Segment by Application
8.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
8.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2027-2032)
8.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Celltrion,Inc.
9.1.1 Celltrion,Inc. Details
9.1.2 Celltrion,Inc. Major Business
9.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.1.4 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Celltrion,Inc. Recent Developments/Updates
9.1.6 Celltrion,Inc. Competitive Strengths & Weaknesses
9.2 SamsungBioepisCo.,Ltd.
9.2.1 SamsungBioepisCo.,Ltd. Details
9.2.2 SamsungBioepisCo.,Ltd. Major Business
9.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.2.4 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 SamsungBioepisCo.,Ltd. Recent Developments/Updates
9.2.6 SamsungBioepisCo.,Ltd. Competitive Strengths & Weaknesses
9.3 AmgenInc.
9.3.1 AmgenInc. Details
9.3.2 AmgenInc. Major Business
9.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.3.4 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AmgenInc. Recent Developments/Updates
9.3.6 AmgenInc. Competitive Strengths & Weaknesses
9.4 SandozGroupAG
9.4.1 SandozGroupAG Details
9.4.2 SandozGroupAG Major Business
9.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.4.4 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 SandozGroupAG Recent Developments/Updates
9.4.6 SandozGroupAG Competitive Strengths & Weaknesses
9.5 PfizerInc.
9.5.1 PfizerInc. Details
9.5.2 PfizerInc. Major Business
9.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.5.4 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 PfizerInc. Recent Developments/Updates
9.5.6 PfizerInc. Competitive Strengths & Weaknesses
9.6 BioconBiologicsLimited
9.6.1 BioconBiologicsLimited Details
9.6.2 BioconBiologicsLimited Major Business
9.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.6.4 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 BioconBiologicsLimited Recent Developments/Updates
9.6.6 BioconBiologicsLimited Competitive Strengths & Weaknesses
9.7 FreseniusKabiAG
9.7.1 FreseniusKabiAG Details
9.7.2 FreseniusKabiAG Major Business
9.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.7.4 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 FreseniusKabiAG Recent Developments/Updates
9.7.6 FreseniusKabiAG Competitive Strengths & Weaknesses
9.8 FormyconAG
9.8.1 FormyconAG Details
9.8.2 FormyconAG Major Business
9.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.8.4 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 FormyconAG Recent Developments/Updates
9.8.6 FormyconAG Competitive Strengths & Weaknesses
9.9 Alvotech
9.9.1 Alvotech Details
9.9.2 Alvotech Major Business
9.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.9.4 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Alvotech Recent Developments/Updates
9.9.6 Alvotech Competitive Strengths & Weaknesses
9.10 TevaPharmaceuticalIndustriesLtd.
9.10.1 TevaPharmaceuticalIndustriesLtd. Details
9.10.2 TevaPharmaceuticalIndustriesLtd. Major Business
9.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.10.4 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 TevaPharmaceuticalIndustriesLtd. Recent Developments/Updates
9.10.6 TevaPharmaceuticalIndustriesLtd. Competitive Strengths & Weaknesses
9.11 Organon&Co.
9.11.1 Organon&Co. Details
9.11.2 Organon&Co. Major Business
9.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.11.4 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Organon&Co. Recent Developments/Updates
9.11.6 Organon&Co. Competitive Strengths & Weaknesses
9.12 BoehringerIngelheimInternationalGmbH
9.12.1 BoehringerIngelheimInternationalGmbH Details
9.12.2 BoehringerIngelheimInternationalGmbH Major Business
9.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.12.4 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 BoehringerIngelheimInternationalGmbH Recent Developments/Updates
9.12.6 BoehringerIngelheimInternationalGmbH Competitive Strengths & Weaknesses
9.13 CoherusBioSciences,Inc.
9.13.1 CoherusBioSciences,Inc. Details
9.13.2 CoherusBioSciences,Inc. Major Business
9.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.13.4 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 CoherusBioSciences,Inc. Recent Developments/Updates
9.13.6 CoherusBioSciences,Inc. Competitive Strengths & Weaknesses
9.14 mAbxience
9.14.1 mAbxience Details
9.14.2 mAbxience Major Business
9.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.14.4 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 mAbxience Recent Developments/Updates
9.14.6 mAbxience Competitive Strengths & Weaknesses
9.15 STADAArzneimittelAG
9.15.1 STADAArzneimittelAG Details
9.15.2 STADAArzneimittelAG Major Business
9.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.15.4 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 STADAArzneimittelAG Recent Developments/Updates
9.15.6 STADAArzneimittelAG Competitive Strengths & Weaknesses
9.16 GedeonRichterPlc.
9.16.1 GedeonRichterPlc. Details
9.16.2 GedeonRichterPlc. Major Business
9.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.16.4 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 GedeonRichterPlc. Recent Developments/Updates
9.16.6 GedeonRichterPlc. Competitive Strengths & Weaknesses
9.17 Bio-TheraSolutions,Ltd.
9.17.1 Bio-TheraSolutions,Ltd. Details
9.17.2 Bio-TheraSolutions,Ltd. Major Business
9.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.17.4 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Bio-TheraSolutions,Ltd. Recent Developments/Updates
9.17.6 Bio-TheraSolutions,Ltd. Competitive Strengths & Weaknesses
9.18 ShanghaiHenliusBiotech,Inc.
9.18.1 ShanghaiHenliusBiotech,Inc. Details
9.18.2 ShanghaiHenliusBiotech,Inc. Major Business
9.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.18.4 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 ShanghaiHenliusBiotech,Inc. Recent Developments/Updates
9.18.6 ShanghaiHenliusBiotech,Inc. Competitive Strengths & Weaknesses
9.19 QiluPharmaceuticalCo.,Ltd.
9.19.1 QiluPharmaceuticalCo.,Ltd. Details
9.19.2 QiluPharmaceuticalCo.,Ltd. Major Business
9.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.19.4 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 QiluPharmaceuticalCo.,Ltd. Recent Developments/Updates
9.19.6 QiluPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
9.20 InnoventBiologics,Inc.
9.20.1 InnoventBiologics,Inc. Details
9.20.2 InnoventBiologics,Inc. Major Business
9.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.20.4 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 InnoventBiologics,Inc. Recent Developments/Updates
9.20.6 InnoventBiologics,Inc. Competitive Strengths & Weaknesses
9.21 Dr.Reddy’sLaboratoriesLtd.
9.21.1 Dr.Reddy’sLaboratoriesLtd. Details
9.21.2 Dr.Reddy’sLaboratoriesLtd. Major Business
9.21.3 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.21.4 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Dr.Reddy’sLaboratoriesLtd. Recent Developments/Updates
9.21.6 Dr.Reddy’sLaboratoriesLtd. Competitive Strengths & Weaknesses
9.22 IntasPharmaceuticalsLtd.
9.22.1 IntasPharmaceuticalsLtd. Details
9.22.2 IntasPharmaceuticalsLtd. Major Business
9.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.22.4 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 IntasPharmaceuticalsLtd. Recent Developments/Updates
9.22.6 IntasPharmaceuticalsLtd. Competitive Strengths & Weaknesses
9.23 AccordHealthcare
9.23.1 AccordHealthcare Details
9.23.2 AccordHealthcare Major Business
9.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.23.4 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 AccordHealthcare Recent Developments/Updates
9.23.6 AccordHealthcare Competitive Strengths & Weaknesses
9.24 LupinLimited
9.24.1 LupinLimited Details
9.24.2 LupinLimited Major Business
9.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.24.4 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 LupinLimited Recent Developments/Updates
9.24.6 LupinLimited Competitive Strengths & Weaknesses
9.25 ZydusLifesciencesLimited
9.25.1 ZydusLifesciencesLimited Details
9.25.2 ZydusLifesciencesLimited Major Business
9.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.25.4 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 ZydusLifesciencesLimited Recent Developments/Updates
9.25.6 ZydusLifesciencesLimited Competitive Strengths & Weaknesses
9.26 RelianceLifeSciencesPvt.Ltd.
9.26.1 RelianceLifeSciencesPvt.Ltd. Details
9.26.2 RelianceLifeSciencesPvt.Ltd. Major Business
9.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.26.4 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 RelianceLifeSciencesPvt.Ltd. Recent Developments/Updates
9.26.6 RelianceLifeSciencesPvt.Ltd. Competitive Strengths & Weaknesses
9.27 PrestigeBiopharmaLimited
9.27.1 PrestigeBiopharmaLimited Details
9.27.2 PrestigeBiopharmaLimited Major Business
9.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.27.4 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 PrestigeBiopharmaLimited Recent Developments/Updates
9.27.6 PrestigeBiopharmaLimited Competitive Strengths & Weaknesses
9.28 AmnealPharmaceuticals,Inc.
9.28.1 AmnealPharmaceuticals,Inc. Details
9.28.2 AmnealPharmaceuticals,Inc. Major Business
9.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.28.4 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 AmnealPharmaceuticals,Inc. Recent Developments/Updates
9.28.6 AmnealPharmaceuticals,Inc. Competitive Strengths & Weaknesses
9.29 PolpharmaBiologicsB.V.
9.29.1 PolpharmaBiologicsB.V. Details
9.29.2 PolpharmaBiologicsB.V. Major Business
9.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.29.4 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 PolpharmaBiologicsB.V. Recent Developments/Updates
9.29.6 PolpharmaBiologicsB.V. Competitive Strengths & Weaknesses
9.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
9.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Details
9.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
9.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments/Updates
9.30.6 Mabwell(Shanghai)BioscienceCo.,Ltd. Competitive Strengths & Weaknesses
9.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
9.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Details
9.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
9.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments/Updates
9.31.6 ZhejiangHisunPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
9.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
9.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Details
9.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
9.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments/Updates
9.32.6 JiangsuHengruiPharmaceuticalsCo.,Ltd. Competitive Strengths & Weaknesses
9.33 LivzonPharmaceuticalGroupInc.
9.33.1 LivzonPharmaceuticalGroupInc. Details
9.33.2 LivzonPharmaceuticalGroupInc. Major Business
9.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.33.4 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.33.5 LivzonPharmaceuticalGroupInc. Recent Developments/Updates
9.33.6 LivzonPharmaceuticalGroupInc. Competitive Strengths & Weaknesses
9.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
9.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details
9.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
9.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments/Updates
9.34.6 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Competitive Strengths & Weaknesses
9.35 MabpharmLimited
9.35.1 MabpharmLimited Details
9.35.2 MabpharmLimited Major Business
9.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.35.4 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.35.5 MabpharmLimited Recent Developments/Updates
9.35.6 MabpharmLimited Competitive Strengths & Weaknesses
9.36 BioXpressTherapeuticsSA
9.36.1 BioXpressTherapeuticsSA Details
9.36.2 BioXpressTherapeuticsSA Major Business
9.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.36.4 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.36.5 BioXpressTherapeuticsSA Recent Developments/Updates
9.36.6 BioXpressTherapeuticsSA Competitive Strengths & Weaknesses
9.37 TanvexBioPharma,Inc.
9.37.1 TanvexBioPharma,Inc. Details
9.37.2 TanvexBioPharma,Inc. Major Business
9.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.37.4 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.37.5 TanvexBioPharma,Inc. Recent Developments/Updates
9.37.6 TanvexBioPharma,Inc. Competitive Strengths & Weaknesses
9.38 CelltrionHealthcare
9.38.1 CelltrionHealthcare Details
9.38.2 CelltrionHealthcare Major Business
9.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.38.4 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.38.5 CelltrionHealthcare Recent Developments/Updates
9.38.6 CelltrionHealthcare Competitive Strengths & Weaknesses
9.39 AmegaBiotech
9.39.1 AmegaBiotech Details
9.39.2 AmegaBiotech Major Business
9.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.39.4 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.39.5 AmegaBiotech Recent Developments/Updates
9.39.6 AmegaBiotech Competitive Strengths & Weaknesses
9.40 ProbiomedS.A.deC.V.
9.40.1 ProbiomedS.A.deC.V. Details
9.40.2 ProbiomedS.A.deC.V. Major Business
9.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.40.4 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.40.5 ProbiomedS.A.deC.V. Recent Developments/Updates
9.40.6 ProbiomedS.A.deC.V. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Monoclonal Antibodies (mAbs) Biosimilars Industry Chain
10.2 Monoclonal Antibodies (mAbs) Biosimilars Upstream Analysis
10.3 Monoclonal Antibodies (mAbs) Biosimilars Midstream Analysis
10.4 Monoclonal Antibodies (mAbs) Biosimilars Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Monoclonal Antibodies (mAbs) Biosimilars Introduction
1.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Monoclonal Antibodies (mAbs) Biosimilars Total Market by Region (by Headquarter Location)
1.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.3 China Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.4 Europe Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.5 Japan Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.6 South Korea Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.7 ASEAN Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.3.8 India Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.2 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region
2.2.1 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026)
2.2.2 World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Region (2027-2032)
2.3 United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.4 China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.5 Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.6 Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.7 South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.8 ASEAN Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
2.9 India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032)
3 WORLD MONOCLONAL ANTIBODIES (MABS) BIOSIMILARS COMPANIES COMPETITIVE ANALYSIS
3.1 World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Monoclonal Antibodies (mAbs) Biosimilars Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Monoclonal Antibodies (mAbs) Biosimilars in 2025
3.2.3 Global Concentration Ratios (CR8) for Monoclonal Antibodies (mAbs) Biosimilars in 2025
3.3 Monoclonal Antibodies (mAbs) Biosimilars Company Evaluation Quadrant
3.4 Monoclonal Antibodies (mAbs) Biosimilars Market: Overall Company Footprint Analysis
3.4.1 Monoclonal Antibodies (mAbs) Biosimilars Market: Region Footprint
3.4.2 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
3.4.3 Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison
4.2.1 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies and Market Share, 2021-2026
4.3.1 United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026)
4.4 China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue and Market Share, 2021-2026
4.4.1 China Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026)
4.5 Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Adalimumab Biosimilars
5.2.2 Infliximab Biosimilars
5.2.3 Rituximab Biosimilars
5.2.4 Trastuzumab Biosimilars
5.2.5 Bevacizumab Biosimilars
5.2.6 Ranibizumab Biosimilars
5.2.7 Ustekinumab Biosimilars
5.2.8 Tocilizumab Biosimilars
5.2.9 Denosumab Biosimilars
5.3 Market Segment by Type
5.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2021-2026)
5.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2027-2032)
5.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Intravenous Infusion Vials
6.2.2 Subcutaneous Prefilled Syringes
6.2.3 Autoinjectors
6.2.4 Lyophilized Powder for Injection
6.2.5 Concentrate for Solution for Infusion
6.2.6 Ophthalmic Intravitreal Injection
6.2.7 Multiple Presentations
6.3 Market Segment by Dosage Form
6.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2021-2026)
6.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2027-2032)
6.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2027-2032)
7 MARKET ANALYSIS BY MOLECULAR TARGET
7.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Molecular Target: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Molecular Target
7.2.1 TNF-? Inhibitors
7.2.2 CD20-targeting Antibodies
7.2.3 HER2-targeting Antibodies
7.2.4 VEGF/VEGF-A Inhibitors
7.2.5 IL-6R Inhibitors
7.2.6 IL-12/23 Inhibitors
7.2.7 RANKL Inhibitors
7.2.8 C5 Complement Inhibitors
7.2.9 IgE Inhibitors
7.3 Market Segment by Molecular Target
7.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2021-2026)
7.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2027-2032)
7.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Oncology
8.2.2 Autoimmune and Inflammatory Diseases
8.2.3 Ophthalmology
8.2.4 Bone Disease and Osteoporosis
8.2.5 Hematology and Rare Diseases
8.2.6 Asthma and Allergy
8.2.7 Other
8.3 Market Segment by Application
8.3.1 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026)
8.3.2 World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2027-2032)
8.3.3 World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Celltrion,Inc.
9.1.1 Celltrion,Inc. Details
9.1.2 Celltrion,Inc. Major Business
9.1.3 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.1.4 Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Celltrion,Inc. Recent Developments/Updates
9.1.6 Celltrion,Inc. Competitive Strengths & Weaknesses
9.2 SamsungBioepisCo.,Ltd.
9.2.1 SamsungBioepisCo.,Ltd. Details
9.2.2 SamsungBioepisCo.,Ltd. Major Business
9.2.3 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.2.4 SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 SamsungBioepisCo.,Ltd. Recent Developments/Updates
9.2.6 SamsungBioepisCo.,Ltd. Competitive Strengths & Weaknesses
9.3 AmgenInc.
9.3.1 AmgenInc. Details
9.3.2 AmgenInc. Major Business
9.3.3 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.3.4 AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 AmgenInc. Recent Developments/Updates
9.3.6 AmgenInc. Competitive Strengths & Weaknesses
9.4 SandozGroupAG
9.4.1 SandozGroupAG Details
9.4.2 SandozGroupAG Major Business
9.4.3 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.4.4 SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 SandozGroupAG Recent Developments/Updates
9.4.6 SandozGroupAG Competitive Strengths & Weaknesses
9.5 PfizerInc.
9.5.1 PfizerInc. Details
9.5.2 PfizerInc. Major Business
9.5.3 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.5.4 PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 PfizerInc. Recent Developments/Updates
9.5.6 PfizerInc. Competitive Strengths & Weaknesses
9.6 BioconBiologicsLimited
9.6.1 BioconBiologicsLimited Details
9.6.2 BioconBiologicsLimited Major Business
9.6.3 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.6.4 BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 BioconBiologicsLimited Recent Developments/Updates
9.6.6 BioconBiologicsLimited Competitive Strengths & Weaknesses
9.7 FreseniusKabiAG
9.7.1 FreseniusKabiAG Details
9.7.2 FreseniusKabiAG Major Business
9.7.3 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.7.4 FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 FreseniusKabiAG Recent Developments/Updates
9.7.6 FreseniusKabiAG Competitive Strengths & Weaknesses
9.8 FormyconAG
9.8.1 FormyconAG Details
9.8.2 FormyconAG Major Business
9.8.3 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.8.4 FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 FormyconAG Recent Developments/Updates
9.8.6 FormyconAG Competitive Strengths & Weaknesses
9.9 Alvotech
9.9.1 Alvotech Details
9.9.2 Alvotech Major Business
9.9.3 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.9.4 Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Alvotech Recent Developments/Updates
9.9.6 Alvotech Competitive Strengths & Weaknesses
9.10 TevaPharmaceuticalIndustriesLtd.
9.10.1 TevaPharmaceuticalIndustriesLtd. Details
9.10.2 TevaPharmaceuticalIndustriesLtd. Major Business
9.10.3 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.10.4 TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 TevaPharmaceuticalIndustriesLtd. Recent Developments/Updates
9.10.6 TevaPharmaceuticalIndustriesLtd. Competitive Strengths & Weaknesses
9.11 Organon&Co.
9.11.1 Organon&Co. Details
9.11.2 Organon&Co. Major Business
9.11.3 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.11.4 Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Organon&Co. Recent Developments/Updates
9.11.6 Organon&Co. Competitive Strengths & Weaknesses
9.12 BoehringerIngelheimInternationalGmbH
9.12.1 BoehringerIngelheimInternationalGmbH Details
9.12.2 BoehringerIngelheimInternationalGmbH Major Business
9.12.3 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.12.4 BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 BoehringerIngelheimInternationalGmbH Recent Developments/Updates
9.12.6 BoehringerIngelheimInternationalGmbH Competitive Strengths & Weaknesses
9.13 CoherusBioSciences,Inc.
9.13.1 CoherusBioSciences,Inc. Details
9.13.2 CoherusBioSciences,Inc. Major Business
9.13.3 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.13.4 CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 CoherusBioSciences,Inc. Recent Developments/Updates
9.13.6 CoherusBioSciences,Inc. Competitive Strengths & Weaknesses
9.14 mAbxience
9.14.1 mAbxience Details
9.14.2 mAbxience Major Business
9.14.3 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.14.4 mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 mAbxience Recent Developments/Updates
9.14.6 mAbxience Competitive Strengths & Weaknesses
9.15 STADAArzneimittelAG
9.15.1 STADAArzneimittelAG Details
9.15.2 STADAArzneimittelAG Major Business
9.15.3 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.15.4 STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 STADAArzneimittelAG Recent Developments/Updates
9.15.6 STADAArzneimittelAG Competitive Strengths & Weaknesses
9.16 GedeonRichterPlc.
9.16.1 GedeonRichterPlc. Details
9.16.2 GedeonRichterPlc. Major Business
9.16.3 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.16.4 GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 GedeonRichterPlc. Recent Developments/Updates
9.16.6 GedeonRichterPlc. Competitive Strengths & Weaknesses
9.17 Bio-TheraSolutions,Ltd.
9.17.1 Bio-TheraSolutions,Ltd. Details
9.17.2 Bio-TheraSolutions,Ltd. Major Business
9.17.3 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.17.4 Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Bio-TheraSolutions,Ltd. Recent Developments/Updates
9.17.6 Bio-TheraSolutions,Ltd. Competitive Strengths & Weaknesses
9.18 ShanghaiHenliusBiotech,Inc.
9.18.1 ShanghaiHenliusBiotech,Inc. Details
9.18.2 ShanghaiHenliusBiotech,Inc. Major Business
9.18.3 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.18.4 ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 ShanghaiHenliusBiotech,Inc. Recent Developments/Updates
9.18.6 ShanghaiHenliusBiotech,Inc. Competitive Strengths & Weaknesses
9.19 QiluPharmaceuticalCo.,Ltd.
9.19.1 QiluPharmaceuticalCo.,Ltd. Details
9.19.2 QiluPharmaceuticalCo.,Ltd. Major Business
9.19.3 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.19.4 QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 QiluPharmaceuticalCo.,Ltd. Recent Developments/Updates
9.19.6 QiluPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
9.20 InnoventBiologics,Inc.
9.20.1 InnoventBiologics,Inc. Details
9.20.2 InnoventBiologics,Inc. Major Business
9.20.3 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.20.4 InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 InnoventBiologics,Inc. Recent Developments/Updates
9.20.6 InnoventBiologics,Inc. Competitive Strengths & Weaknesses
9.21 Dr.Reddy’sLaboratoriesLtd.
9.21.1 Dr.Reddy’sLaboratoriesLtd. Details
9.21.2 Dr.Reddy’sLaboratoriesLtd. Major Business
9.21.3 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.21.4 Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Dr.Reddy’sLaboratoriesLtd. Recent Developments/Updates
9.21.6 Dr.Reddy’sLaboratoriesLtd. Competitive Strengths & Weaknesses
9.22 IntasPharmaceuticalsLtd.
9.22.1 IntasPharmaceuticalsLtd. Details
9.22.2 IntasPharmaceuticalsLtd. Major Business
9.22.3 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.22.4 IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 IntasPharmaceuticalsLtd. Recent Developments/Updates
9.22.6 IntasPharmaceuticalsLtd. Competitive Strengths & Weaknesses
9.23 AccordHealthcare
9.23.1 AccordHealthcare Details
9.23.2 AccordHealthcare Major Business
9.23.3 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.23.4 AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 AccordHealthcare Recent Developments/Updates
9.23.6 AccordHealthcare Competitive Strengths & Weaknesses
9.24 LupinLimited
9.24.1 LupinLimited Details
9.24.2 LupinLimited Major Business
9.24.3 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.24.4 LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 LupinLimited Recent Developments/Updates
9.24.6 LupinLimited Competitive Strengths & Weaknesses
9.25 ZydusLifesciencesLimited
9.25.1 ZydusLifesciencesLimited Details
9.25.2 ZydusLifesciencesLimited Major Business
9.25.3 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.25.4 ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 ZydusLifesciencesLimited Recent Developments/Updates
9.25.6 ZydusLifesciencesLimited Competitive Strengths & Weaknesses
9.26 RelianceLifeSciencesPvt.Ltd.
9.26.1 RelianceLifeSciencesPvt.Ltd. Details
9.26.2 RelianceLifeSciencesPvt.Ltd. Major Business
9.26.3 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.26.4 RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 RelianceLifeSciencesPvt.Ltd. Recent Developments/Updates
9.26.6 RelianceLifeSciencesPvt.Ltd. Competitive Strengths & Weaknesses
9.27 PrestigeBiopharmaLimited
9.27.1 PrestigeBiopharmaLimited Details
9.27.2 PrestigeBiopharmaLimited Major Business
9.27.3 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.27.4 PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 PrestigeBiopharmaLimited Recent Developments/Updates
9.27.6 PrestigeBiopharmaLimited Competitive Strengths & Weaknesses
9.28 AmnealPharmaceuticals,Inc.
9.28.1 AmnealPharmaceuticals,Inc. Details
9.28.2 AmnealPharmaceuticals,Inc. Major Business
9.28.3 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.28.4 AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 AmnealPharmaceuticals,Inc. Recent Developments/Updates
9.28.6 AmnealPharmaceuticals,Inc. Competitive Strengths & Weaknesses
9.29 PolpharmaBiologicsB.V.
9.29.1 PolpharmaBiologicsB.V. Details
9.29.2 PolpharmaBiologicsB.V. Major Business
9.29.3 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.29.4 PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 PolpharmaBiologicsB.V. Recent Developments/Updates
9.29.6 PolpharmaBiologicsB.V. Competitive Strengths & Weaknesses
9.30 Mabwell(Shanghai)BioscienceCo.,Ltd.
9.30.1 Mabwell(Shanghai)BioscienceCo.,Ltd. Details
9.30.2 Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
9.30.3 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.30.4 Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments/Updates
9.30.6 Mabwell(Shanghai)BioscienceCo.,Ltd. Competitive Strengths & Weaknesses
9.31 ZhejiangHisunPharmaceuticalCo.,Ltd.
9.31.1 ZhejiangHisunPharmaceuticalCo.,Ltd. Details
9.31.2 ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
9.31.3 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.31.4 ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments/Updates
9.31.6 ZhejiangHisunPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
9.32 JiangsuHengruiPharmaceuticalsCo.,Ltd.
9.32.1 JiangsuHengruiPharmaceuticalsCo.,Ltd. Details
9.32.2 JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
9.32.3 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.32.4 JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.32.5 JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments/Updates
9.32.6 JiangsuHengruiPharmaceuticalsCo.,Ltd. Competitive Strengths & Weaknesses
9.33 LivzonPharmaceuticalGroupInc.
9.33.1 LivzonPharmaceuticalGroupInc. Details
9.33.2 LivzonPharmaceuticalGroupInc. Major Business
9.33.3 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.33.4 LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.33.5 LivzonPharmaceuticalGroupInc. Recent Developments/Updates
9.33.6 LivzonPharmaceuticalGroupInc. Competitive Strengths & Weaknesses
9.34 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd.
9.34.1 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Details
9.34.2 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
9.34.3 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.34.4 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.34.5 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments/Updates
9.34.6 SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Competitive Strengths & Weaknesses
9.35 MabpharmLimited
9.35.1 MabpharmLimited Details
9.35.2 MabpharmLimited Major Business
9.35.3 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.35.4 MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.35.5 MabpharmLimited Recent Developments/Updates
9.35.6 MabpharmLimited Competitive Strengths & Weaknesses
9.36 BioXpressTherapeuticsSA
9.36.1 BioXpressTherapeuticsSA Details
9.36.2 BioXpressTherapeuticsSA Major Business
9.36.3 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.36.4 BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.36.5 BioXpressTherapeuticsSA Recent Developments/Updates
9.36.6 BioXpressTherapeuticsSA Competitive Strengths & Weaknesses
9.37 TanvexBioPharma,Inc.
9.37.1 TanvexBioPharma,Inc. Details
9.37.2 TanvexBioPharma,Inc. Major Business
9.37.3 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.37.4 TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.37.5 TanvexBioPharma,Inc. Recent Developments/Updates
9.37.6 TanvexBioPharma,Inc. Competitive Strengths & Weaknesses
9.38 CelltrionHealthcare
9.38.1 CelltrionHealthcare Details
9.38.2 CelltrionHealthcare Major Business
9.38.3 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.38.4 CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.38.5 CelltrionHealthcare Recent Developments/Updates
9.38.6 CelltrionHealthcare Competitive Strengths & Weaknesses
9.39 AmegaBiotech
9.39.1 AmegaBiotech Details
9.39.2 AmegaBiotech Major Business
9.39.3 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.39.4 AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.39.5 AmegaBiotech Recent Developments/Updates
9.39.6 AmegaBiotech Competitive Strengths & Weaknesses
9.40 ProbiomedS.A.deC.V.
9.40.1 ProbiomedS.A.deC.V. Details
9.40.2 ProbiomedS.A.deC.V. Major Business
9.40.3 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
9.40.4 ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026)
9.40.5 ProbiomedS.A.deC.V. Recent Developments/Updates
9.40.6 ProbiomedS.A.deC.V. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Monoclonal Antibodies (mAbs) Biosimilars Industry Chain
10.2 Monoclonal Antibodies (mAbs) Biosimilars Upstream Analysis
10.3 Monoclonal Antibodies (mAbs) Biosimilars Midstream Analysis
10.4 Monoclonal Antibodies (mAbs) Biosimilars Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Monoclonal Antibodies (mAbs) Biosimilars Players in 2025
Table 12. World Monoclonal Antibodies (mAbs) Biosimilars Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Monoclonal Antibodies (mAbs) Biosimilars Company Evaluation Quadrant
Table 14. Head Office of Key Monoclonal Antibodies (mAbs) Biosimilars Players
Table 15. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
Table 16. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
Table 17. Monoclonal Antibodies (mAbs) Biosimilars Mergers & Acquisitions Activity
Table 18. United States VS China Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (States, Country)
Table 21. United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 23. China Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
Table 24. China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 26. Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 29. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2027-2032) & (USD Million)
Table 32. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 33. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Dosage Form (2021-2026) & (USD Million)
Table 34. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2027-2032) & (USD Million)
Table 35. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target, (USD Million), 2021 & 2025 & 2032
Table 36. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Molecular Target (2021-2026) & (USD Million)
Table 37. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2027-2032) & (USD Million)
Table 38. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & (USD Million)
Table 40. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2027-2032) & (USD Million)
Table 41. Celltrion,Inc. Basic Information, Manufacturing Base and Competitors
Table 42. Celltrion,Inc. Major Business
Table 43. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 44. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Celltrion,Inc. Recent Developments/Updates
Table 46. Celltrion,Inc. Competitive Strengths & Weaknesses
Table 47. SamsungBioepisCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 48. SamsungBioepisCo.,Ltd. Major Business
Table 49. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 50. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. SamsungBioepisCo.,Ltd. Recent Developments/Updates
Table 52. SamsungBioepisCo.,Ltd. Competitive Strengths & Weaknesses
Table 53. AmgenInc. Basic Information, Manufacturing Base and Competitors
Table 54. AmgenInc. Major Business
Table 55. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 56. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AmgenInc. Recent Developments/Updates
Table 58. AmgenInc. Competitive Strengths & Weaknesses
Table 59. SandozGroupAG Basic Information, Manufacturing Base and Competitors
Table 60. SandozGroupAG Major Business
Table 61. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 62. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. SandozGroupAG Recent Developments/Updates
Table 64. SandozGroupAG Competitive Strengths & Weaknesses
Table 65. PfizerInc. Basic Information, Manufacturing Base and Competitors
Table 66. PfizerInc. Major Business
Table 67. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 68. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. PfizerInc. Recent Developments/Updates
Table 70. PfizerInc. Competitive Strengths & Weaknesses
Table 71. BioconBiologicsLimited Basic Information, Manufacturing Base and Competitors
Table 72. BioconBiologicsLimited Major Business
Table 73. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 74. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. BioconBiologicsLimited Recent Developments/Updates
Table 76. BioconBiologicsLimited Competitive Strengths & Weaknesses
Table 77. FreseniusKabiAG Basic Information, Manufacturing Base and Competitors
Table 78. FreseniusKabiAG Major Business
Table 79. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 80. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. FreseniusKabiAG Recent Developments/Updates
Table 82. FreseniusKabiAG Competitive Strengths & Weaknesses
Table 83. FormyconAG Basic Information, Manufacturing Base and Competitors
Table 84. FormyconAG Major Business
Table 85. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 86. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. FormyconAG Recent Developments/Updates
Table 88. FormyconAG Competitive Strengths & Weaknesses
Table 89. Alvotech Basic Information, Manufacturing Base and Competitors
Table 90. Alvotech Major Business
Table 91. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 92. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Alvotech Recent Developments/Updates
Table 94. Alvotech Competitive Strengths & Weaknesses
Table 95. TevaPharmaceuticalIndustriesLtd. Basic Information, Manufacturing Base and Competitors
Table 96. TevaPharmaceuticalIndustriesLtd. Major Business
Table 97. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 98. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. TevaPharmaceuticalIndustriesLtd. Recent Developments/Updates
Table 100. TevaPharmaceuticalIndustriesLtd. Competitive Strengths & Weaknesses
Table 101. Organon&Co. Basic Information, Manufacturing Base and Competitors
Table 102. Organon&Co. Major Business
Table 103. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 104. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Organon&Co. Recent Developments/Updates
Table 106. Organon&Co. Competitive Strengths & Weaknesses
Table 107. BoehringerIngelheimInternationalGmbH Basic Information, Manufacturing Base and Competitors
Table 108. BoehringerIngelheimInternationalGmbH Major Business
Table 109. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 110. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. BoehringerIngelheimInternationalGmbH Recent Developments/Updates
Table 112. BoehringerIngelheimInternationalGmbH Competitive Strengths & Weaknesses
Table 113. CoherusBioSciences,Inc. Basic Information, Manufacturing Base and Competitors
Table 114. CoherusBioSciences,Inc. Major Business
Table 115. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 116. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. CoherusBioSciences,Inc. Recent Developments/Updates
Table 118. CoherusBioSciences,Inc. Competitive Strengths & Weaknesses
Table 119. mAbxience Basic Information, Manufacturing Base and Competitors
Table 120. mAbxience Major Business
Table 121. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 122. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. mAbxience Recent Developments/Updates
Table 124. mAbxience Competitive Strengths & Weaknesses
Table 125. STADAArzneimittelAG Basic Information, Manufacturing Base and Competitors
Table 126. STADAArzneimittelAG Major Business
Table 127. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 128. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. STADAArzneimittelAG Recent Developments/Updates
Table 130. STADAArzneimittelAG Competitive Strengths & Weaknesses
Table 131. GedeonRichterPlc. Basic Information, Manufacturing Base and Competitors
Table 132. GedeonRichterPlc. Major Business
Table 133. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 134. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. GedeonRichterPlc. Recent Developments/Updates
Table 136. GedeonRichterPlc. Competitive Strengths & Weaknesses
Table 137. Bio-TheraSolutions,Ltd. Basic Information, Manufacturing Base and Competitors
Table 138. Bio-TheraSolutions,Ltd. Major Business
Table 139. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 140. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Bio-TheraSolutions,Ltd. Recent Developments/Updates
Table 142. Bio-TheraSolutions,Ltd. Competitive Strengths & Weaknesses
Table 143. ShanghaiHenliusBiotech,Inc. Basic Information, Manufacturing Base and Competitors
Table 144. ShanghaiHenliusBiotech,Inc. Major Business
Table 145. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 146. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. ShanghaiHenliusBiotech,Inc. Recent Developments/Updates
Table 148. ShanghaiHenliusBiotech,Inc. Competitive Strengths & Weaknesses
Table 149. QiluPharmaceuticalCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. QiluPharmaceuticalCo.,Ltd. Major Business
Table 151. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 152. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. QiluPharmaceuticalCo.,Ltd. Recent Developments/Updates
Table 154. QiluPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
Table 155. InnoventBiologics,Inc. Basic Information, Manufacturing Base and Competitors
Table 156. InnoventBiologics,Inc. Major Business
Table 157. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 158. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. InnoventBiologics,Inc. Recent Developments/Updates
Table 160. InnoventBiologics,Inc. Competitive Strengths & Weaknesses
Table 161. Dr.Reddy’sLaboratoriesLtd. Basic Information, Manufacturing Base and Competitors
Table 162. Dr.Reddy’sLaboratoriesLtd. Major Business
Table 163. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 164. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Dr.Reddy’sLaboratoriesLtd. Recent Developments/Updates
Table 166. Dr.Reddy’sLaboratoriesLtd. Competitive Strengths & Weaknesses
Table 167. IntasPharmaceuticalsLtd. Basic Information, Manufacturing Base and Competitors
Table 168. IntasPharmaceuticalsLtd. Major Business
Table 169. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 170. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. IntasPharmaceuticalsLtd. Recent Developments/Updates
Table 172. IntasPharmaceuticalsLtd. Competitive Strengths & Weaknesses
Table 173. AccordHealthcare Basic Information, Manufacturing Base and Competitors
Table 174. AccordHealthcare Major Business
Table 175. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 176. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. AccordHealthcare Recent Developments/Updates
Table 178. AccordHealthcare Competitive Strengths & Weaknesses
Table 179. LupinLimited Basic Information, Manufacturing Base and Competitors
Table 180. LupinLimited Major Business
Table 181. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 182. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. LupinLimited Recent Developments/Updates
Table 184. LupinLimited Competitive Strengths & Weaknesses
Table 185. ZydusLifesciencesLimited Basic Information, Manufacturing Base and Competitors
Table 186. ZydusLifesciencesLimited Major Business
Table 187. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 188. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. ZydusLifesciencesLimited Recent Developments/Updates
Table 190. ZydusLifesciencesLimited Competitive Strengths & Weaknesses
Table 191. RelianceLifeSciencesPvt.Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. RelianceLifeSciencesPvt.Ltd. Major Business
Table 193. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 194. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. RelianceLifeSciencesPvt.Ltd. Recent Developments/Updates
Table 196. RelianceLifeSciencesPvt.Ltd. Competitive Strengths & Weaknesses
Table 197. PrestigeBiopharmaLimited Basic Information, Manufacturing Base and Competitors
Table 198. PrestigeBiopharmaLimited Major Business
Table 199. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 200. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. PrestigeBiopharmaLimited Recent Developments/Updates
Table 202. PrestigeBiopharmaLimited Competitive Strengths & Weaknesses
Table 203. AmnealPharmaceuticals,Inc. Basic Information, Manufacturing Base and Competitors
Table 204. AmnealPharmaceuticals,Inc. Major Business
Table 205. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 206. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. AmnealPharmaceuticals,Inc. Recent Developments/Updates
Table 208. AmnealPharmaceuticals,Inc. Competitive Strengths & Weaknesses
Table 209. PolpharmaBiologicsB.V. Basic Information, Manufacturing Base and Competitors
Table 210. PolpharmaBiologicsB.V. Major Business
Table 211. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 212. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. PolpharmaBiologicsB.V. Recent Developments/Updates
Table 214. PolpharmaBiologicsB.V. Competitive Strengths & Weaknesses
Table 215. Mabwell(Shanghai)BioscienceCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 216. Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
Table 217. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 218. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments/Updates
Table 220. Mabwell(Shanghai)BioscienceCo.,Ltd. Competitive Strengths & Weaknesses
Table 221. ZhejiangHisunPharmaceuticalCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 222. ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
Table 223. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 224. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments/Updates
Table 226. ZhejiangHisunPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
Table 227. JiangsuHengruiPharmaceuticalsCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 228. JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
Table 229. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 230. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 231. JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments/Updates
Table 232. JiangsuHengruiPharmaceuticalsCo.,Ltd. Competitive Strengths & Weaknesses
Table 233. LivzonPharmaceuticalGroupInc. Basic Information, Manufacturing Base and Competitors
Table 234. LivzonPharmaceuticalGroupInc. Major Business
Table 235. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 236. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 237. LivzonPharmaceuticalGroupInc. Recent Developments/Updates
Table 238. LivzonPharmaceuticalGroupInc. Competitive Strengths & Weaknesses
Table 239. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 240. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
Table 241. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 242. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 243. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments/Updates
Table 244. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Competitive Strengths & Weaknesses
Table 245. MabpharmLimited Basic Information, Manufacturing Base and Competitors
Table 246. MabpharmLimited Major Business
Table 247. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 248. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 249. MabpharmLimited Recent Developments/Updates
Table 250. MabpharmLimited Competitive Strengths & Weaknesses
Table 251. BioXpressTherapeuticsSA Basic Information, Manufacturing Base and Competitors
Table 252. BioXpressTherapeuticsSA Major Business
Table 253. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 254. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 255. BioXpressTherapeuticsSA Recent Developments/Updates
Table 256. BioXpressTherapeuticsSA Competitive Strengths & Weaknesses
Table 257. TanvexBioPharma,Inc. Basic Information, Manufacturing Base and Competitors
Table 258. TanvexBioPharma,Inc. Major Business
Table 259. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 260. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 261. TanvexBioPharma,Inc. Recent Developments/Updates
Table 262. TanvexBioPharma,Inc. Competitive Strengths & Weaknesses
Table 263. CelltrionHealthcare Basic Information, Manufacturing Base and Competitors
Table 264. CelltrionHealthcare Major Business
Table 265. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 266. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 267. CelltrionHealthcare Recent Developments/Updates
Table 268. CelltrionHealthcare Competitive Strengths & Weaknesses
Table 269. AmegaBiotech Basic Information, Manufacturing Base and Competitors
Table 270. AmegaBiotech Major Business
Table 271. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 272. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 273. AmegaBiotech Recent Developments/Updates
Table 274. AmegaBiotech Competitive Strengths & Weaknesses
Table 275. ProbiomedS.A.deC.V. Basic Information, Manufacturing Base and Competitors
Table 276. ProbiomedS.A.deC.V. Major Business
Table 277. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 278. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 279. ProbiomedS.A.deC.V. Recent Developments/Updates
Table 280. ProbiomedS.A.deC.V. Competitive Strengths & Weaknesses
Table 281. Global Key Players of Monoclonal Antibodies (mAbs) Biosimilars Upstream (Raw Materials)
Table 282. Global Monoclonal Antibodies (mAbs) Biosimilars Typical Customers
Table 1. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Monoclonal Antibodies (mAbs) Biosimilars Players in 2025
Table 12. World Monoclonal Antibodies (mAbs) Biosimilars Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Monoclonal Antibodies (mAbs) Biosimilars Company Evaluation Quadrant
Table 14. Head Office of Key Monoclonal Antibodies (mAbs) Biosimilars Players
Table 15. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Type Footprint
Table 16. Monoclonal Antibodies (mAbs) Biosimilars Market: Company Product Application Footprint
Table 17. Monoclonal Antibodies (mAbs) Biosimilars Mergers & Acquisitions Activity
Table 18. United States VS China Monoclonal Antibodies (mAbs) Biosimilars Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (States, Country)
Table 21. United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 23. China Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
Table 24. China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 26. Rest of World Based Monoclonal Antibodies (mAbs) Biosimilars Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share (2021-2026)
Table 29. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type (2027-2032) & (USD Million)
Table 32. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 33. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Dosage Form (2021-2026) & (USD Million)
Table 34. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form (2027-2032) & (USD Million)
Table 35. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target, (USD Million), 2021 & 2025 & 2032
Table 36. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Value by Molecular Target (2021-2026) & (USD Million)
Table 37. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target (2027-2032) & (USD Million)
Table 38. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2021-2026) & (USD Million)
Table 40. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application (2027-2032) & (USD Million)
Table 41. Celltrion,Inc. Basic Information, Manufacturing Base and Competitors
Table 42. Celltrion,Inc. Major Business
Table 43. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 44. Celltrion,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Celltrion,Inc. Recent Developments/Updates
Table 46. Celltrion,Inc. Competitive Strengths & Weaknesses
Table 47. SamsungBioepisCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 48. SamsungBioepisCo.,Ltd. Major Business
Table 49. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 50. SamsungBioepisCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. SamsungBioepisCo.,Ltd. Recent Developments/Updates
Table 52. SamsungBioepisCo.,Ltd. Competitive Strengths & Weaknesses
Table 53. AmgenInc. Basic Information, Manufacturing Base and Competitors
Table 54. AmgenInc. Major Business
Table 55. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 56. AmgenInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. AmgenInc. Recent Developments/Updates
Table 58. AmgenInc. Competitive Strengths & Weaknesses
Table 59. SandozGroupAG Basic Information, Manufacturing Base and Competitors
Table 60. SandozGroupAG Major Business
Table 61. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 62. SandozGroupAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. SandozGroupAG Recent Developments/Updates
Table 64. SandozGroupAG Competitive Strengths & Weaknesses
Table 65. PfizerInc. Basic Information, Manufacturing Base and Competitors
Table 66. PfizerInc. Major Business
Table 67. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 68. PfizerInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. PfizerInc. Recent Developments/Updates
Table 70. PfizerInc. Competitive Strengths & Weaknesses
Table 71. BioconBiologicsLimited Basic Information, Manufacturing Base and Competitors
Table 72. BioconBiologicsLimited Major Business
Table 73. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 74. BioconBiologicsLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. BioconBiologicsLimited Recent Developments/Updates
Table 76. BioconBiologicsLimited Competitive Strengths & Weaknesses
Table 77. FreseniusKabiAG Basic Information, Manufacturing Base and Competitors
Table 78. FreseniusKabiAG Major Business
Table 79. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 80. FreseniusKabiAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. FreseniusKabiAG Recent Developments/Updates
Table 82. FreseniusKabiAG Competitive Strengths & Weaknesses
Table 83. FormyconAG Basic Information, Manufacturing Base and Competitors
Table 84. FormyconAG Major Business
Table 85. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 86. FormyconAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. FormyconAG Recent Developments/Updates
Table 88. FormyconAG Competitive Strengths & Weaknesses
Table 89. Alvotech Basic Information, Manufacturing Base and Competitors
Table 90. Alvotech Major Business
Table 91. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 92. Alvotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Alvotech Recent Developments/Updates
Table 94. Alvotech Competitive Strengths & Weaknesses
Table 95. TevaPharmaceuticalIndustriesLtd. Basic Information, Manufacturing Base and Competitors
Table 96. TevaPharmaceuticalIndustriesLtd. Major Business
Table 97. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 98. TevaPharmaceuticalIndustriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. TevaPharmaceuticalIndustriesLtd. Recent Developments/Updates
Table 100. TevaPharmaceuticalIndustriesLtd. Competitive Strengths & Weaknesses
Table 101. Organon&Co. Basic Information, Manufacturing Base and Competitors
Table 102. Organon&Co. Major Business
Table 103. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 104. Organon&Co. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Organon&Co. Recent Developments/Updates
Table 106. Organon&Co. Competitive Strengths & Weaknesses
Table 107. BoehringerIngelheimInternationalGmbH Basic Information, Manufacturing Base and Competitors
Table 108. BoehringerIngelheimInternationalGmbH Major Business
Table 109. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 110. BoehringerIngelheimInternationalGmbH Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. BoehringerIngelheimInternationalGmbH Recent Developments/Updates
Table 112. BoehringerIngelheimInternationalGmbH Competitive Strengths & Weaknesses
Table 113. CoherusBioSciences,Inc. Basic Information, Manufacturing Base and Competitors
Table 114. CoherusBioSciences,Inc. Major Business
Table 115. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 116. CoherusBioSciences,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. CoherusBioSciences,Inc. Recent Developments/Updates
Table 118. CoherusBioSciences,Inc. Competitive Strengths & Weaknesses
Table 119. mAbxience Basic Information, Manufacturing Base and Competitors
Table 120. mAbxience Major Business
Table 121. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 122. mAbxience Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. mAbxience Recent Developments/Updates
Table 124. mAbxience Competitive Strengths & Weaknesses
Table 125. STADAArzneimittelAG Basic Information, Manufacturing Base and Competitors
Table 126. STADAArzneimittelAG Major Business
Table 127. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 128. STADAArzneimittelAG Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. STADAArzneimittelAG Recent Developments/Updates
Table 130. STADAArzneimittelAG Competitive Strengths & Weaknesses
Table 131. GedeonRichterPlc. Basic Information, Manufacturing Base and Competitors
Table 132. GedeonRichterPlc. Major Business
Table 133. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 134. GedeonRichterPlc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. GedeonRichterPlc. Recent Developments/Updates
Table 136. GedeonRichterPlc. Competitive Strengths & Weaknesses
Table 137. Bio-TheraSolutions,Ltd. Basic Information, Manufacturing Base and Competitors
Table 138. Bio-TheraSolutions,Ltd. Major Business
Table 139. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 140. Bio-TheraSolutions,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Bio-TheraSolutions,Ltd. Recent Developments/Updates
Table 142. Bio-TheraSolutions,Ltd. Competitive Strengths & Weaknesses
Table 143. ShanghaiHenliusBiotech,Inc. Basic Information, Manufacturing Base and Competitors
Table 144. ShanghaiHenliusBiotech,Inc. Major Business
Table 145. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 146. ShanghaiHenliusBiotech,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. ShanghaiHenliusBiotech,Inc. Recent Developments/Updates
Table 148. ShanghaiHenliusBiotech,Inc. Competitive Strengths & Weaknesses
Table 149. QiluPharmaceuticalCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. QiluPharmaceuticalCo.,Ltd. Major Business
Table 151. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 152. QiluPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. QiluPharmaceuticalCo.,Ltd. Recent Developments/Updates
Table 154. QiluPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
Table 155. InnoventBiologics,Inc. Basic Information, Manufacturing Base and Competitors
Table 156. InnoventBiologics,Inc. Major Business
Table 157. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 158. InnoventBiologics,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. InnoventBiologics,Inc. Recent Developments/Updates
Table 160. InnoventBiologics,Inc. Competitive Strengths & Weaknesses
Table 161. Dr.Reddy’sLaboratoriesLtd. Basic Information, Manufacturing Base and Competitors
Table 162. Dr.Reddy’sLaboratoriesLtd. Major Business
Table 163. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 164. Dr.Reddy’sLaboratoriesLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Dr.Reddy’sLaboratoriesLtd. Recent Developments/Updates
Table 166. Dr.Reddy’sLaboratoriesLtd. Competitive Strengths & Weaknesses
Table 167. IntasPharmaceuticalsLtd. Basic Information, Manufacturing Base and Competitors
Table 168. IntasPharmaceuticalsLtd. Major Business
Table 169. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 170. IntasPharmaceuticalsLtd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. IntasPharmaceuticalsLtd. Recent Developments/Updates
Table 172. IntasPharmaceuticalsLtd. Competitive Strengths & Weaknesses
Table 173. AccordHealthcare Basic Information, Manufacturing Base and Competitors
Table 174. AccordHealthcare Major Business
Table 175. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 176. AccordHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. AccordHealthcare Recent Developments/Updates
Table 178. AccordHealthcare Competitive Strengths & Weaknesses
Table 179. LupinLimited Basic Information, Manufacturing Base and Competitors
Table 180. LupinLimited Major Business
Table 181. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 182. LupinLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. LupinLimited Recent Developments/Updates
Table 184. LupinLimited Competitive Strengths & Weaknesses
Table 185. ZydusLifesciencesLimited Basic Information, Manufacturing Base and Competitors
Table 186. ZydusLifesciencesLimited Major Business
Table 187. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 188. ZydusLifesciencesLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. ZydusLifesciencesLimited Recent Developments/Updates
Table 190. ZydusLifesciencesLimited Competitive Strengths & Weaknesses
Table 191. RelianceLifeSciencesPvt.Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. RelianceLifeSciencesPvt.Ltd. Major Business
Table 193. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 194. RelianceLifeSciencesPvt.Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. RelianceLifeSciencesPvt.Ltd. Recent Developments/Updates
Table 196. RelianceLifeSciencesPvt.Ltd. Competitive Strengths & Weaknesses
Table 197. PrestigeBiopharmaLimited Basic Information, Manufacturing Base and Competitors
Table 198. PrestigeBiopharmaLimited Major Business
Table 199. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 200. PrestigeBiopharmaLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. PrestigeBiopharmaLimited Recent Developments/Updates
Table 202. PrestigeBiopharmaLimited Competitive Strengths & Weaknesses
Table 203. AmnealPharmaceuticals,Inc. Basic Information, Manufacturing Base and Competitors
Table 204. AmnealPharmaceuticals,Inc. Major Business
Table 205. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 206. AmnealPharmaceuticals,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. AmnealPharmaceuticals,Inc. Recent Developments/Updates
Table 208. AmnealPharmaceuticals,Inc. Competitive Strengths & Weaknesses
Table 209. PolpharmaBiologicsB.V. Basic Information, Manufacturing Base and Competitors
Table 210. PolpharmaBiologicsB.V. Major Business
Table 211. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 212. PolpharmaBiologicsB.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. PolpharmaBiologicsB.V. Recent Developments/Updates
Table 214. PolpharmaBiologicsB.V. Competitive Strengths & Weaknesses
Table 215. Mabwell(Shanghai)BioscienceCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 216. Mabwell(Shanghai)BioscienceCo.,Ltd. Major Business
Table 217. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 218. Mabwell(Shanghai)BioscienceCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Mabwell(Shanghai)BioscienceCo.,Ltd. Recent Developments/Updates
Table 220. Mabwell(Shanghai)BioscienceCo.,Ltd. Competitive Strengths & Weaknesses
Table 221. ZhejiangHisunPharmaceuticalCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 222. ZhejiangHisunPharmaceuticalCo.,Ltd. Major Business
Table 223. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 224. ZhejiangHisunPharmaceuticalCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. ZhejiangHisunPharmaceuticalCo.,Ltd. Recent Developments/Updates
Table 226. ZhejiangHisunPharmaceuticalCo.,Ltd. Competitive Strengths & Weaknesses
Table 227. JiangsuHengruiPharmaceuticalsCo.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 228. JiangsuHengruiPharmaceuticalsCo.,Ltd. Major Business
Table 229. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 230. JiangsuHengruiPharmaceuticalsCo.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 231. JiangsuHengruiPharmaceuticalsCo.,Ltd. Recent Developments/Updates
Table 232. JiangsuHengruiPharmaceuticalsCo.,Ltd. Competitive Strengths & Weaknesses
Table 233. LivzonPharmaceuticalGroupInc. Basic Information, Manufacturing Base and Competitors
Table 234. LivzonPharmaceuticalGroupInc. Major Business
Table 235. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 236. LivzonPharmaceuticalGroupInc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 237. LivzonPharmaceuticalGroupInc. Recent Developments/Updates
Table 238. LivzonPharmaceuticalGroupInc. Competitive Strengths & Weaknesses
Table 239. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Basic Information, Manufacturing Base and Competitors
Table 240. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Major Business
Table 241. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 242. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 243. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Recent Developments/Updates
Table 244. SunshineGuojianPharmaceutical(Shanghai)Co.,Ltd. Competitive Strengths & Weaknesses
Table 245. MabpharmLimited Basic Information, Manufacturing Base and Competitors
Table 246. MabpharmLimited Major Business
Table 247. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 248. MabpharmLimited Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 249. MabpharmLimited Recent Developments/Updates
Table 250. MabpharmLimited Competitive Strengths & Weaknesses
Table 251. BioXpressTherapeuticsSA Basic Information, Manufacturing Base and Competitors
Table 252. BioXpressTherapeuticsSA Major Business
Table 253. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 254. BioXpressTherapeuticsSA Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 255. BioXpressTherapeuticsSA Recent Developments/Updates
Table 256. BioXpressTherapeuticsSA Competitive Strengths & Weaknesses
Table 257. TanvexBioPharma,Inc. Basic Information, Manufacturing Base and Competitors
Table 258. TanvexBioPharma,Inc. Major Business
Table 259. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 260. TanvexBioPharma,Inc. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 261. TanvexBioPharma,Inc. Recent Developments/Updates
Table 262. TanvexBioPharma,Inc. Competitive Strengths & Weaknesses
Table 263. CelltrionHealthcare Basic Information, Manufacturing Base and Competitors
Table 264. CelltrionHealthcare Major Business
Table 265. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 266. CelltrionHealthcare Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 267. CelltrionHealthcare Recent Developments/Updates
Table 268. CelltrionHealthcare Competitive Strengths & Weaknesses
Table 269. AmegaBiotech Basic Information, Manufacturing Base and Competitors
Table 270. AmegaBiotech Major Business
Table 271. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 272. AmegaBiotech Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 273. AmegaBiotech Recent Developments/Updates
Table 274. AmegaBiotech Competitive Strengths & Weaknesses
Table 275. ProbiomedS.A.deC.V. Basic Information, Manufacturing Base and Competitors
Table 276. ProbiomedS.A.deC.V. Major Business
Table 277. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Product and Services
Table 278. ProbiomedS.A.deC.V. Monoclonal Antibodies (mAbs) Biosimilars Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 279. ProbiomedS.A.deC.V. Recent Developments/Updates
Table 280. ProbiomedS.A.deC.V. Competitive Strengths & Weaknesses
Table 281. Global Key Players of Monoclonal Antibodies (mAbs) Biosimilars Upstream (Raw Materials)
Table 282. Global Monoclonal Antibodies (mAbs) Biosimilars Typical Customers
LIST OF FIGURES
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Picture
Figure 2. World Monoclonal Antibodies (mAbs) Biosimilars Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Monoclonal Antibodies (mAbs) Biosimilars Total Revenue (2021-2032) & (USD Million)
Figure 4. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 13. Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 16. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 18. China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 23. India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Monoclonal Antibodies (mAbs) Biosimilars by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Monoclonal Antibodies (mAbs) Biosimilars Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Monoclonal Antibodies (mAbs) Biosimilars Markets in 2025
Figure 27. United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type in 2025
Figure 31. Adalimumab Biosimilars
Figure 32. Infliximab Biosimilars
Figure 33. Rituximab Biosimilars
Figure 34. Trastuzumab Biosimilars
Figure 35. Bevacizumab Biosimilars
Figure 36. Ranibizumab Biosimilars
Figure 37. Ustekinumab Biosimilars
Figure 38. Tocilizumab Biosimilars
Figure 39. Ustekinumab Biosimilars
Figure 40. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2032)
Figure 41. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 42. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form in 2025
Figure 43. Intravenous Infusion Vials
Figure 44. Subcutaneous Prefilled Syringes
Figure 45. Autoinjectors
Figure 46. Lyophilized Powder for Injection
Figure 47. Concentrate for Solution for Infusion
Figure 48. Ophthalmic Intravitreal Injection
Figure 49. Multiple Presentations
Figure 50. Multiple Presentations
Figure 51. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2032)
Figure 52. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target, (USD Million), 2021 & 2025 & 2032
Figure 53. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target in 2025
Figure 54. TNF-? Inhibitors
Figure 55. CD20-targeting Antibodies
Figure 56. HER2-targeting Antibodies
Figure 57. VEGF/VEGF-A Inhibitors
Figure 58. IL-6R Inhibitors
Figure 59. IL-12/23 Inhibitors
Figure 60. RANKL Inhibitors
Figure 61. C5 Complement Inhibitors
Figure 62. RANKL Inhibitors
Figure 63. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2032)
Figure 64. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 65. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application in 2025
Figure 66. Oncology
Figure 67. Autoimmune and Inflammatory Diseases
Figure 68. Ophthalmology
Figure 69. Bone Disease and Osteoporosis
Figure 70. Hematology and Rare Diseases
Figure 71. Asthma and Allergy
Figure 72. Other
Figure 73. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2032)
Figure 74. Monoclonal Antibodies (mAbs) Biosimilars Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
Figure 1. Monoclonal Antibodies (mAbs) Biosimilars Picture
Figure 2. World Monoclonal Antibodies (mAbs) Biosimilars Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Monoclonal Antibodies (mAbs) Biosimilars Total Revenue (2021-2032) & (USD Million)
Figure 4. World Monoclonal Antibodies (mAbs) Biosimilars Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Monoclonal Antibodies (mAbs) Biosimilars Revenue (2021-2032) & (USD Million)
Figure 13. Monoclonal Antibodies (mAbs) Biosimilars Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 16. World Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 18. China Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 23. India Monoclonal Antibodies (mAbs) Biosimilars Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Monoclonal Antibodies (mAbs) Biosimilars by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Monoclonal Antibodies (mAbs) Biosimilars Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Monoclonal Antibodies (mAbs) Biosimilars Markets in 2025
Figure 27. United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Monoclonal Antibodies (mAbs) Biosimilars Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type in 2025
Figure 31. Adalimumab Biosimilars
Figure 32. Infliximab Biosimilars
Figure 33. Rituximab Biosimilars
Figure 34. Trastuzumab Biosimilars
Figure 35. Bevacizumab Biosimilars
Figure 36. Ranibizumab Biosimilars
Figure 37. Ustekinumab Biosimilars
Figure 38. Tocilizumab Biosimilars
Figure 39. Ustekinumab Biosimilars
Figure 40. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Type (2021-2032)
Figure 41. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 42. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form in 2025
Figure 43. Intravenous Infusion Vials
Figure 44. Subcutaneous Prefilled Syringes
Figure 45. Autoinjectors
Figure 46. Lyophilized Powder for Injection
Figure 47. Concentrate for Solution for Infusion
Figure 48. Ophthalmic Intravitreal Injection
Figure 49. Multiple Presentations
Figure 50. Multiple Presentations
Figure 51. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Dosage Form (2021-2032)
Figure 52. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Molecular Target, (USD Million), 2021 & 2025 & 2032
Figure 53. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target in 2025
Figure 54. TNF-? Inhibitors
Figure 55. CD20-targeting Antibodies
Figure 56. HER2-targeting Antibodies
Figure 57. VEGF/VEGF-A Inhibitors
Figure 58. IL-6R Inhibitors
Figure 59. IL-12/23 Inhibitors
Figure 60. RANKL Inhibitors
Figure 61. C5 Complement Inhibitors
Figure 62. RANKL Inhibitors
Figure 63. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Molecular Target (2021-2032)
Figure 64. World Monoclonal Antibodies (mAbs) Biosimilars Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 65. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application in 2025
Figure 66. Oncology
Figure 67. Autoimmune and Inflammatory Diseases
Figure 68. Ophthalmology
Figure 69. Bone Disease and Osteoporosis
Figure 70. Hematology and Rare Diseases
Figure 71. Asthma and Allergy
Figure 72. Other
Figure 73. World Monoclonal Antibodies (mAbs) Biosimilars Market Size Market Share by Application (2021-2032)
Figure 74. Monoclonal Antibodies (mAbs) Biosimilars Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
